Home

Search Abstracts

Browse Sessions

Program Committee

Conference Webcasts

Contact Us

---

Session 80   Poster Abstracts Antiretroviral Therapy: Predictors of Response and Virologic Failure Monday, 1:30 - 3:30 pm Poster Hall

547	Efficacy and Safety of Atazanavir with Ritonavir or Saquinavir vs Lopinavir/Ritonavir in Patients Who Have Experienced Virologic Failure on Multiple HAART Regimens: 48-Week Results from BMS A1424-045 E DeJesus1, B Grinsztejn2, C Rodriguez3, L Nieto-Cisneros4, J Coco5, A Lazzarin6, K Lichtenstein7, M Johnson*8, A Rightmire9, S Sankoh10, and R Wilber10 1IDC Res. Initiative, Altamonte Springs, Florida, USA; 2Inst. de Pesquisa Clin. Evandro Chagas-Fiocruz, Rio de Janeiro, Brazil; 3Hosp. Argerich, Buenos Aires, Argentina; 4Hosp. Gabriel Mancera, IMSS Mexico, D.F., Mexico; 5Pendleton Memorial Methodist Hosp., New Orleans, LA, USA; 6S. Raffaele Hosp., Milan, Italy; 7Univ. of Colorado Hlth. Sci. Ctr., Denver, USA; 8Royal Free Hosp., London, UK; 9Bristol-Myers Squibb Co., Hopewell, NJ, USA; and 10Bristol-Myers Squibb Co., Wallingford, CT, USA
548	A Randomized Trial of 1 or 2 Protease Inhibitors in Combination with a Non-nucleoside Reverse Transcriptase Inhibitor and Background Therapy in Patients with Virologic Failure on an Initial Protease-inhibitor Containing Regimen J Kostman*1, B Grund2, R Leduc2, J Baxter3,4, L Crane5, and Terry Beirn Community Programs for Clinical Research on AIDS 1Univ. of Pennsylvania Hlth. System, Philadelphia, USA; 2Univ. of Minnesota, Minneapolis, USA; 3Cooper Hosp.; 4Robert Wood Johnson Med. Sch., Camden, NJ, USA; and 5Wayne State Univ., Detroit, MI, USA
549	Final Week 48 Analysis of a Phase 4, Randomised, Open-label, Multi-center Trial to Evaluate Safety and Efficacy of Continued Lamivudine Twice Daily Versus Discontinuation of Lamivudine in HIV-1-infected Adults with Virological Failure on Ongoing Combination Treatments Containing Lamivudine: The COLATE Trial U Dragsted*1, Z Fox1, L Mathiesen2, C Katlama3, M Youle4, J Gerstoft5, J N Bruun6, and J D Lundgren for the COLATE trial group1 1Copenhagen HIV Prgm., Hvidovre Univ. Hosp., Denmark; 2Hvidovre Univ. Hosp., Copenhagen, Denmark; 3Hosp. de la Pitié- Salpêtriére, Paris, France; 4Royal Free Hosp., London, UK; 5Rigshospitalet, Copenhagen, Denmark; and 6Ullevål Univ. Hosp., Oslo, Norway
550	Virologic Failure in Antiretroviral Therapy Naive Patients Is Only Determined by Extreme Low Values of CD4+ Cells or High Values of HIV-1 RNA Concentration, Not by Choice of Treatment with Nevirapine or Efavirenz F van Leth*1, S Andrews2, B Grinsztjen3, E Wilkins4, M Lazanas5, J Lange1,6, J Montaner7, and for the 2NN study group 1Intl. Antiviral Therapy Evaluation Ctr., Amsterdam, The Netherlands; 2Brooklyn Med. Ctr., Cape Town, South Africa; 3Ctr. de Pesquisa Hosp. Evandro Chagas, Rio de Janeiro, Brazil; 4North Manchester Gen. Hosp., UK; 5Gen. Hosp. 'Korgialenio-Benakio-Hellenic Red Cross', Athens, Greece; 6Academic Med. Ctr., Univ. of Amsterdam, The Netherlands; and 7St. Paul's Hosp., Vancouver, Canada
551	Analysis of Virologic Failure in a Clinical Trial of Abacavir Once Daily versus Twice Daily with Lamivudine and Efavirenz C Craig*1, C Stone1, T Bonny2, H Zhao2, D Gordon3, S Castillo2, and D Paes3 1GlaxoSmithKline, Stevenage, UK; 2GlaxoSmithKline, Research Triangle Park, NC, USA; and 3GlaxoSmithKline, Greenford, UK
552	Emergence of Resistance Mutations During Intermittent HAART. Rate, Predicting Factors, and Effect on Virologic Response L Palmisano, M Giuliano, R Bucciardini, C M Galluzzo, M Andreotti, V Fragola, R Arcieri, R Amici, L Weimer, E Germinario, M F Pirillo, S Vella*, and The Italian ISS PART Clinical Centers Inst. Superiore di Sanita, Rome, Italy
553	Factors Associated with Virologic Failure and Their Impact on Treatment Outcomes: An Analysis of Virologic Failure in ACTG 388 H Ribaudo*1, G Downey1, M Fischl2, J Feinberg3, A Erice4, and A Collier5 1Harvard Sch. of Publ. Hlth., Boston, MA, USA; 2Univ. of Miami, FL, USA; 3Univ. of Cincinnati, OH, USA; 4Hosp. Asepeyo, Madrid, Spain; and 5Univ. of Washington, Seattle, USA
554	Time to Triple Drug Class Failure after Initiation of HAART A Mocroft*1, B Ledergerber2, J P Viard3, S Staszewski4, M Murphy5, A Chiesi6, A Horban7, A B Hansen8, A N Phillips1, J D Lundgren9, and the EuroSIDA study group 1Royal Free and Univ. Coll. Med. Sch., London, UK; 2Univ. Hosp. Zurich, Switzerland; 3Hosp. Necker-Enfants Malades, Paris, France; 4JW Goethe Univ. Hosp., Frankfurt, Germany; 5St. Bartholemews Hosp., London, UK; 6Inst. Superiore di Sanita, Rome, Italy; 7Ctr. Diagnostyki i Terapii AIDS, Warsaw, Poland; 8Rigshospitalet, Copenhagen, Denmark; and 9Hvidovre Hosp., Copenhagen, Denmark
555	Factors Associated with Improved Survival among Heavily Antiretroviral Treatment Experienced Patients in the HIV Outpatient Study F J Palella Jr*1, J S Chmiel1, K A Kirby1, A C Moorman2, S D Holmberg2, and the HOPS investigators 1Northwestern Univ., Chicago, IL, USA and 2CDC, Atlanta, GA, USA
556	Response to HAART in HIV-infected Persons Older than 50 Years R Moore*, J Keruly, K Gebo, G Lucas, and R Chaisson Johns Hopkins Univ., Baltimore, MD. USA
557	Low Baseline CD4 T-cell Count and Higher Age Predict Poor CD4 T-cell Recovery in Treated HIV-1 Infected Individuals Suppressing HIV-1 RNA to Levels <1000 copies/mL for 5 Years G Kaufmann*1, H Furrer2, L Perrin3, C Ungsedhapand1, M Opravil4, M Egger5, M Cavassini6, P Vernazza7, E Bernasconi8, M Rickenbach9, B Hirschel10, M Battegay1, and the Swiss HIV Cohort Study 1Univ. Hosp. Basel, Switzerland; 2Univ. Hosp. Berne, Switzerland; 3Lab. of Virology, Univ. Hosp. Geneva, Switzerland; 4Univ. Hosp. Zurich, Switzerland; 5Univ. of Berne, Switzerland; 6CHUV, Switzerland; 7Cantonal Hosp. St.Gallen, Switzerland; 8Regional Hosp., Lugano, Switzerland; 9Data Ctr. of the SHCS, CHUV, Switzerland; and 10Univ. Hosp. Geneva, Switzerland
558	Improvement in Virologic, Immunologic, and Clinical Outcomes in Clinical Practice from 1996 to 2002 R Moore*, J Keruly, K Gebo, and G Lucas Johns Hopkins Univ., Baltimore, MD. USA
559	The Use of Observational Databases to Compare Anti-retroviral Effectiveness P Keiser*1, N Nassar1, B Yazdani1, L Armas2, and S Moreno1,2 1Univ. of Texas Southwestern Med. Ctr., Dallas, USA and 2Parkland Hlth. and Hosp. System, Dallas, TX, USA
560	Effect of Race on the Response to Highly-Active Antiretroviral Therapy K Anastos*1,2, and M Schneider3 1Montefiore Med. Ctr., Bronx, NY, USA; 2Lincoln Med. and Mental Hlth.; and 3Johns Hopkins Bloomberg Sch. of Publ. Hlth., Baltimore, MD, USA
561	Hemoglobin as a Prognostic Factor for AIDS-defining Illness and Survival with the Use of HAART R Moore*, and J Keruly Johns Hopkins Univ., Baltimore, MD. USA
562	Impact of an Adherence Clinic on Behavioral Outcomes and Virologic Response: Results from a Prospective, Randomized, Controlled Pilot Study R Rathbun*1, K Farmer1, J Stephens2, and S Lockhart1 1Univ. of Oklahoma Hlth. Sci. Ctr., Oklahoma City, USA and 2Univ. of Oklahoma Schusterman Ctr., Tulsa, USA
563	Comparison of Directly Administered Antiretroviral Therapy in a Methadone Clinic and Self-Administered Therapy in HIV-infected Patients G Lucas*1, P Weidle2, S Hader2, and R Moore1 1Johns Hopkins Univ., Baltimore, MD, USA and 2CDC, Atlanta, GA, USA